Treatment outcome of de novo, non-DS AML-M0 patients treated using CCG-2891-IT and CCG-2961
| . | De novo CCG-2891 (IT) and CCG-2961 . | De novo CCG-2891 (IT) . | De novo CCG-2961* . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | |
| Remission induction rate after 2 courses (4 cycles) | 79 (10) | 78 (2) | .919 | 72 (21) | 81 (4) | .367 | 81 (0) | 76 (3) | .619 |
| Remission induction failures | 15 (9) | 11 (2) | .373 | 22 (19) | 10 (3) | .124 | 13 (9) | 12 (2) | .955 |
| Induction deaths | 6 (6) | 11 (2) | .325 | 6 (11) | 9 (3) | .973 | 7 (7) | 13 (2) | .346 |
| OS from Dx at 8 y | 38 (14) | 51 (3) | .160 | 42 (24) | 49 (5) | .770 | 43 (15) | 58 (4) | .113 |
| EFS from Dx at 8 y | 23 (11) | 41 (3) | .018 | 33 (22) | 40 (4) | .566 | 23 (12) | 45 (4) | .012 |
| OS from EOI at 8 y | 45 (17) | 63 (3) | .038 | 50 (29) | 60 (5) | .765 | 46 (18) | 70 (4) | .011 |
| DFS from EOI at 8 y | 31 (14) | 52 (3) | .009 | 46 (28) | 51 (5) | .919 | 24 (17) | 56 (4) | .001 |
| CIR at 8 y | 65 (14) | 40 (3) | .002 | 54 (28) | 42 (5) | .506 | 71 (17) | 37 (4) | .001 |
| CITRM from EOI at 8 y | 4 (5) | 7 (2) | .441 | 0 (0) | 7 (3) | .311 | 5 (7) | 7 (2) | .775 |
| . | De novo CCG-2891 (IT) and CCG-2961 . | De novo CCG-2891 (IT) . | De novo CCG-2961* . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | AML-M0, % (2SE%) . | Non-M0, % (2SE%) . | P . | |
| Remission induction rate after 2 courses (4 cycles) | 79 (10) | 78 (2) | .919 | 72 (21) | 81 (4) | .367 | 81 (0) | 76 (3) | .619 |
| Remission induction failures | 15 (9) | 11 (2) | .373 | 22 (19) | 10 (3) | .124 | 13 (9) | 12 (2) | .955 |
| Induction deaths | 6 (6) | 11 (2) | .325 | 6 (11) | 9 (3) | .973 | 7 (7) | 13 (2) | .346 |
| OS from Dx at 8 y | 38 (14) | 51 (3) | .160 | 42 (24) | 49 (5) | .770 | 43 (15) | 58 (4) | .113 |
| EFS from Dx at 8 y | 23 (11) | 41 (3) | .018 | 33 (22) | 40 (4) | .566 | 23 (12) | 45 (4) | .012 |
| OS from EOI at 8 y | 45 (17) | 63 (3) | .038 | 50 (29) | 60 (5) | .765 | 46 (18) | 70 (4) | .011 |
| DFS from EOI at 8 y | 31 (14) | 52 (3) | .009 | 46 (28) | 51 (5) | .919 | 24 (17) | 56 (4) | .001 |
| CIR at 8 y | 65 (14) | 40 (3) | .002 | 54 (28) | 42 (5) | .506 | 71 (17) | 37 (4) | .001 |
| CITRM from EOI at 8 y | 4 (5) | 7 (2) | .441 | 0 (0) | 7 (3) | .311 | 5 (7) | 7 (2) | .775 |
For the de novo CCG-2891 and CCG 2961, n = 27 and 1322, respectively, for AML-M0 and non-M0; for de novo CCG-2891, n = 18 and 492, respectively, for AML-M0 and non-M0; and for de novo CCG-2961, n = 54 and 830, respectively, for AML-M0 and non-M0.
SE indicates Greenwood standard error; EOI, end of induction and is considered to be at the end of 2 courses of induction therapy; CIR, cumulative incidence of relapse; CITRM, cumulative incidence of toxicity-related mortality.
Survival figures for CCG-2961 only are reported at 3 years.